Mostrar el registro sencillo del ítem

dc.contributor.authorHerrero-Morant, A.
dc.contributor.authorAlvarez-Reguera, C.
dc.contributor.authorMartin-Varillas, J. L.
dc.contributor.authorCalvo-Rio, V.
dc.contributor.authorCasado, A.
dc.contributor.authorPrieto-Pena, D.
dc.contributor.authorAtienza-Mateo, B.
dc.contributor.authorMaiz-Alonso, O.
dc.contributor.authorBlanco, A.
dc.contributor.authorVicente, E.
dc.contributor.authorRua-Figueroa, I.
dc.contributor.authorCaceres-Martin, L.
dc.contributor.authorGarcia-Serrano, J. L.
dc.contributor.authorCallejas-Rubio, J. L.
dc.contributor.authorOrtego-Centeno, N.
dc.contributor.authorNarvaez, J.
dc.contributor.authorRomero Yuste, Susana María 
dc.contributor.authorSanchez, J.
dc.contributor.authorEstrada, P.
dc.contributor.authorDemetrio-Pablo, R.
dc.contributor.authorMartinez-Lopez, D.
dc.contributor.authorCastaneda, S.
dc.contributor.authorHernandez, J. L.
dc.contributor.authorGonzalez-Gay, M. A.
dc.contributor.authorBlanco, R.
dc.date.accessioned2022-03-23T08:54:02Z
dc.date.available2022-03-23T08:54:02Z
dc.date.issued2020
dc.identifier.issn2077-0383
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32796717es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16356
dc.description.abstractWe aimed to assess the efficacy of biologic therapy in refractory non-Multiple Sclerosis (MS) Optic Neuritis (ON), a condition more infrequent, chronic and severe than MS ON. This was an open-label multicenter study of patients with non-MS ON refractory to systemic corticosteroids and at least one conventional immunosuppressive drug. The main outcomes were Best Corrected Visual Acuity (BCVA) and both Macular Thickness (MT) and Retinal Nerve Fiber Layer (RNFL) using Optical Coherence Tomography (OCT). These outcome variables were assessed at baseline, 1 week, and 1, 3, 6 and 12 months after biologic therapy initiation. Remission was defined as the absence of ON symptoms and signs that lasted longer than 24 h, with or without an associated new lesion on magnetic resonance imaging with gadolinium contrast agents for at least 3 months. We studied 19 patients (11 women/8 men; mean age, 34.8 +/- 13.9 years). The underlying diseases were Bechet's disease (n = 5), neuromyelitis optica (n = 3), systemic lupus erythematosus (n = 2), sarcoidosis (n = 1), relapsing polychondritis (n = 1) and anti-neutrophil cytoplasmic antibody -associated vasculitis (n = 1). It was idiopathic in 6 patients. The first biologic agent used in each patient was: adalimumab (n = 6), rituximab (n = 6), infliximab (n = 5) and tocilizumab (n = 2). A second immunosuppressive drug was simultaneously used in 11 patients: methotrexate (n = 11), azathioprine (n = 2), mycophenolate mofetil (n = 1) and hydroxychloroquine (n = 1). Improvement of the main outcomes was observed after 1 year of therapy when compared with baseline data: mean +/- SD BCVA (0.8 +/- 0.3 LogMAR vs. 0.6 +/- 0.3 LogMAR; p = 0.03), mean +/- SD RNFL (190.5 +/- 175.4 mum vs. 183.4 +/- 139.5 mum; p = 0.02), mean +/- SD MT (270.7 +/- 23.2 mum vs. 369.6 +/- 137.4 mum; p = 0.03). Besides, the median (IQR) prednisone-dose was also reduced from 40 (10-61.5) mg/day at baseline to. 2.5 (0-5) mg/day after one year of follow-up; p = 0.001. After a mean +/- SD follow-up of 35 months, 15 patients (78.9%) achieved ocular remission, and 2 (10.5%) experienced severe adverse events. Biologic therapy is effective in patients with refractory non-MS ON.en
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleBiologic therapy in refractory non-multiple sclerosis optic neuritis isolated or associated to immune-mediated inflammatory diseases. A multicenter studyen
dc.typeJournal Articlees
dc.authorsophosHerrero-Morant, A.;Alvarez-Reguera, C.;Martin-Varillas, J. L.;Calvo-Rio, V.;Casado, A.;Prieto-Pena, D.;Atienza-Mateo, B.;Maiz-Alonso, O.;Blanco, A.;Vicente, E.;Rua-Figueroa, I.;Caceres-Martin, L.;Garcia-Serrano, J. L.;Callejas-Rubio, J. L.;Ortego-Centeno, N.;Narvaez, J.;Romero-Yuste, S.;Sanchez, J.;Estrada, P.;Demetrio-Pablo, R.;Martinez-Lopez, D.;Castaneda, S.;Hernandez, J. L.;Gonzalez-Gay, M. A.;Blanco, R.
dc.identifier.doi10.3390/jcm9082608
dc.identifier.pmid32796717
dc.identifier.sophos36586
dc.issue.number8es
dc.journal.titleJournal of Clinical Medicinees
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Pontevedra e O Salnés - Complexo Hospitalario Universitario de Pontevedra::Reumatoloxíaes
dc.page.initial41275es
dc.rights.accessRightsopenAccess
dc.subject.keywordCHUPes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number9es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional